Syon Capital LLC Sells 6,254 Shares of Grifols, S.A. (NASDAQ:GRFS)

Syon Capital LLC cut its stake in Grifols, S.A. (NASDAQ:GRFS) by 22.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 21,072 shares of the biotechnology company’s stock after selling 6,254 shares during the period. Syon Capital LLC’s holdings in Grifols were worth $244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in Grifols by 106.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,132 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,618 shares during the period. Cardinal Capital Management boosted its holdings in Grifols by 10.4% in the 4th quarter. Cardinal Capital Management now owns 93,616 shares of the biotechnology company’s stock valued at $1,082,000 after purchasing an additional 8,789 shares during the period. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Grifols by 6.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 178,413 shares of the biotechnology company’s stock worth $1,631,000 after acquiring an additional 10,954 shares during the period. Jump Financial LLC bought a new position in shares of Grifols during the 3rd quarter worth about $136,000. Finally, Raymond James & Associates bought a new position in shares of Grifols during the 3rd quarter worth about $254,000.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft downgraded shares of Grifols from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th.

Grifols Stock Up 1.8 %

Shares of GRFS stock opened at $6.38 on Friday. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $12.15. The firm has a 50-day moving average price of $6.92 and a 200 day moving average price of $8.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.83 and a quick ratio of 1.32.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.